{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:20:48Z","timestamp":1788880848286,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.autrev.2025.103856","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T12:43:32Z","timestamp":1750423412000},"page":"103856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Radio-labelled fibroblast activation protein inhibitors in interstitial lung diseases \u2013 a systematic review"],"prefix":"10.1016","volume":"24","author":[{"given":"Mads","family":"Bundgaard-Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke Helin","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saher Burhan","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer Tandrup Holst","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10354","key":"10.1016\/j.autrev.2025.103856_bb0005","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitial lung diseases","volume":"400","author":"Wijsenbeek","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.autrev.2025.103856_bb0010","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.autrev.2025.103856_bb0015","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.122.264205","article-title":"Fibroblast activation protein inhibitor imaging in nonmalignant diseases: a new perspective for molecular imaging","volume":"63","author":"Schmidkonz","year":"2022","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.autrev.2025.103856_bb0020","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3390\/biom13121718","article-title":"Fibroblast activation protein alpha (FAP\u03b1) in fibrosis: beyond a perspective marker for activated stromal cells?","volume":"13","author":"Basalova","year":"2023","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.autrev.2025.103856_bb0025","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.autrev.2025.103856_bb0030","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.autrev.2025.103856_bb0035","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/diagnostics13122018","article-title":"FAPI PET\/CT imaging\u2014an updated review","volume":"13","author":"Chandekar","year":"2023","journal-title":"Diagnostics"},{"issue":"2","key":"10.1016\/j.autrev.2025.103856_bb0040","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2967\/jnumed.120.244806","article-title":"The latest developments in imaging of fibroblast activation protein","volume":"62","author":"Altmann","year":"2021","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.autrev.2025.103856_bb0045","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/annrheumdis-2020-217408","article-title":"Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging","volume":"79","author":"Schmidkonz","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103856_bb0050","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.autrev.2025.103856_bb0055","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30421-5","article-title":"68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study","volume":"3","author":"Bergmann","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103856_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102598","article-title":"FAPi PET\/CT for assessment and visualisation of active myositis-related interstitial lung disease: a prospective observational pilot study","volume":"72","author":"Kastrati","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.autrev.2025.103856_bb0065","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/ph17060726","article-title":"[68Ga]FAPI PET for imaging and treatment monitoring in a preclinical model of pulmonary fibrosis: comparison to [18F]FDG PET and CT","volume":"17","author":"Ji","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"11","key":"10.1016\/j.autrev.2025.103856_bb0070","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1007\/s00259-022-05814-9","article-title":"[68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity","volume":"49","author":"Rosenkrans","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.autrev.2025.103856_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-023-02556-6","article-title":"Usefulness of FAP\u03b1 assessment in bronchoalveolar lavage as a marker of fibrogenesis: results of a preclinical study and first report in patients with idiopathic pulmonary fibrosis","volume":"24","author":"Lavis","year":"2023","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.autrev.2025.103856_bb0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13550-024-01118-1","article-title":"Early diagnosis and staging of paraquat-induced pulmonary fibrosis using [18F]F-FAPI-42 PET\/CT imaging","volume":"14","author":"Zhang","year":"2024","journal-title":"EJNMMI Res"},{"issue":"6","key":"10.1016\/j.autrev.2025.103856_bb0085","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s11739-023-03327-3","article-title":"Assessment of pulmonary fibrosis induced by paraquat using Al18F-NODA-FAPI-04 PET\/CT","volume":"18","author":"Song","year":"2023","journal-title":"Intern Emerg Med"},{"issue":"10","key":"10.1016\/j.autrev.2025.103856_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ph16101434","article-title":"99mTc-labeled FAPI SPECT imaging in idiopathic pulmonary fibrosis: preliminary results","volume":"16","author":"Liu","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.autrev.2025.103856_bb0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2967\/jnumed.121.261925","article-title":"Fibroblast activation protein-specific PET\/CT imaging in fibrotic interstitial lung diseases and lung Cancer: a translational exploratory study","volume":"63","author":"R\u00f6hrich","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.autrev.2025.103856_bb0100","article-title":"Initial results with [18F]FAPI-74 PET\/CT in idiopathic pulmonary fibrosis","author":"Mori","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.autrev.2025.103856_bb0105","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1164\/rccm.202110-2414OC","article-title":"Comprehensive analysis of fibroblast activation protein expression in interstitial lung diseases","volume":"207","author":"Yang","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.autrev.2025.103856_bb0110","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2967\/jnumed.124.268351","article-title":"Correlation of FAPI PET uptake with immunohistochemistry in explanted lungs from patients with advanced interstitial lung disease","volume":"65","author":"Hotta","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.autrev.2025.103856_bb0115","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000005505","article-title":"Exploring the potential value of [68Ga]Ga-FAPI-46 PET\/CT for molecular assessment of fibroblast activation in interstitial lung disease a single-center pilot study","author":"Bahtouee","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"11","key":"10.1016\/j.autrev.2025.103856_bb0125","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103856_bb0130","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","article-title":"The European scleroderma trials and research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index","volume":"76","author":"Valentini","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2025.103856_bb0135","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein\u2013targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103856_bb0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s41181-021-00144-x","article-title":"18F-labeled tracers targeting fibroblast activation protein","volume":"6","author":"Lindner","year":"2021","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"12","key":"10.1016\/j.autrev.2025.103856_bb0145","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2967\/jnumed.122.264069","article-title":"Repetitive early 68 Ga-FAPI PET acquisition comparing 68 Ga-FAPI-02, 68 Ga-FAPI-46, and 68 Ga-FAPI-74: methodologic and diagnostic implications for malignant, inflammatory\/reactive, and degenerative lesions","volume":"63","author":"Glatting","year":"2022","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.autrev.2025.103856_bb0150","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.120.245084","article-title":"FAPI-74 PET\/CT using either 18 F-AlF or cold-kit 68 Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients","volume":"62","author":"Giesel","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.autrev.2025.103856_bb0160","series-title":"68Ga- or 18F-FAPI PET\/CT\u2014What It Can and Cannot","author":"Mori","year":"2023"},{"issue":"2","key":"10.1016\/j.autrev.2025.103856_bb0165","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jsps.2022.12.013","article-title":"SPECT\/CT and PET\/CT, related radiopharmaceuticals, and areas of application and comparison","volume":"31","author":"Alqahtani","year":"2023","journal-title":"Saudi Pharmaceut J"},{"issue":"4","key":"10.1016\/j.autrev.2025.103856_bb0170","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s00259-022-06068-1","article-title":"The role of [99mTc]Tc-HFAPi SPECT\/CT in patients with malignancies of digestive system: first clinical experience","volume":"50","author":"Jia","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.autrev.2025.103856_bb0175","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s41181-024-00264-0","article-title":"99mTc-labeled FAPI compounds for cancer and inflammation: from radiochemistry to the first clinical applications","volume":"9","author":"Boschi","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"2","key":"10.1016\/j.autrev.2025.103856_bb0180","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1021\/acs.molpharmaceut.3c00886","article-title":"Synthesis and preliminary study of 99m Tc-labeled HYNIC-FAPi for imaging of fibroblast activation proteins in tumors","volume":"21","author":"Ma","year":"2024","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.autrev.2025.103856_bb0185","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00259-022-06028-9","article-title":"EANM practice guideline for quantitative SPECT-CT","volume":"50","author":"Dickson","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.autrev.2025.103856_bb0190","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/MNM.0000000000000538","article-title":"Multicenter evaluation of single-photon emission computed tomography quantification with third-party reconstruction software","volume":"37","author":"Kangasmaa","year":"2016","journal-title":"Nucl Med Commun"},{"issue":"10","key":"10.1016\/j.autrev.2025.103856_bb0195","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1021\/acs.molpharmaceut.4c00783","article-title":"Prospective Study Comparing [ 99m Tc]Tc-DP-FAPI Quantitative SPECT\/CT with [ 68 Ga]Ga-FAPI-04 PET\/CT in Patients with Gastrointestinal Tumors","volume":"21","author":"Zhou","year":"2024","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.autrev.2025.103856_bb0200","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s00259-022-06081-4","article-title":"Assessment of myocardial fibrosis in patients with systemic sclerosis using [68Ga]Ga-FAPI-04-PET-CT","volume":"50","author":"Treutlein","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.autrev.2025.103856_bb0205","series-title":"Paraquat poisonings: Mechanisms of lung toxicity, clinical features, and treatment","author":"Dinis-Oliveira","year":"2008"},{"key":"10.1016\/j.autrev.2025.103856_bb0210","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.toxlet.2020.08.004","article-title":"Paraquat induces pulmonary fibrosis through Wnt\/\u03b2-catenin signaling pathway and myofibroblast differentiation","volume":"333","author":"Sun","year":"2020","journal-title":"Toxicol Lett"},{"issue":"2","key":"10.1016\/j.autrev.2025.103856_bb0215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0014-4800(89)90027-0","article-title":"Experimental pulmonary fibrosis induced by paraquat plus oxygen in rats: a morphologic and biochemical sequential study","volume":"50","author":"Selman","year":"1989","journal-title":"Exp Mol Pathol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103856_bb0220","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1164\/ajrccm.163.7.2006132","article-title":"Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis","volume":"163","author":"Borzone","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2025.103856_bb0225","series-title":"Methods in molecular biology (Clifton, N.J.)","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4939-7113-8_2","article-title":"The bleomycin model of pulmonary fibrosis","volume":"vol. 1627","author":"Liu","year":"2017"},{"issue":"4","key":"10.1016\/j.autrev.2025.103856_bb0230","doi-asserted-by":"crossref","first-page":"L442","DOI":"10.1152\/ajplung.00026.2010","article-title":"Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis","volume":"299","author":"Degryse","year":"2010","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103856_bb0235","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.biocel.2007.08.011","article-title":"The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?","volume":"40","author":"Moeller","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"issue":"16","key":"10.1016\/j.autrev.2025.103856_bb0240","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156115","article-title":"The UIP\/IPF fibroblastic focus is a collagen biosynthesis factory embedded in a distinct extracellular matrix","volume":"7","author":"Herrera","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.autrev.2025.103856_bb0245","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1172\/JCI93557","article-title":"Extracellular matrix as a driver of progressive fibrosis","volume":"128","author":"Herrera","year":"2018","journal-title":"J Clin Investig"},{"issue":"2","key":"10.1016\/j.autrev.2025.103856_bb0250","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1164\/rccm.2109039","article-title":"The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis","volume":"166","author":"Nicholson","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103856_bb0255","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2967\/jnumed.121.262944","article-title":"Perspective on fibroblast activation protein-specific PET\/CT in fibrotic interstitial lung diseases: imaging fibrosis - a new paradigm for molecular imaging?","volume":"63","author":"Schmidkonz","year":"2022","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.autrev.2025.103856_bb0260","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/resp.14231","article-title":"Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases","volume":"27","author":"Brown","year":"2022","journal-title":"Respirology"},{"issue":"22","key":"10.1016\/j.autrev.2025.103856_bb0265","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of Nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103856_bb0270","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12931-020-1296-3","article-title":"Progression of fibrosing interstitial lung disease","volume":"21","author":"Wong","year":"2020","journal-title":"Respir Res"},{"issue":"7","key":"10.1016\/j.autrev.2025.103856_bb0275","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1164\/rccm.2111053","article-title":"Idiopathic pulmonary fibrosis","volume":"167","author":"Wells","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2025.103856_bb0280","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.113.133801","article-title":"Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: A systematic review and meta-analysis","author":"Pak","year":"2014","journal-title":"Society of Nuclear Medicine Inc"},{"issue":"18","key":"10.1016\/j.autrev.2025.103856_bb0285","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive Fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T03:17:18Z","timestamp":1754795838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1568997225001168"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103856","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radio-labelled fibroblast activation protein inhibitors in interstitial lung diseases \u2013 a systematic review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103856"}}